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ABSTRACT 
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system with a 
substantial genetic component, originally mapped to only the HLA region. In the last 5 years, a 
total of 7 GWAS and one meta-analysis successfully identified 57 non-HLA susceptibility loci. 
Here we merged nominal statistical evidence of association with physical evidence of 
interaction to conduct a protein interaction network-based pathway analysis on two large 
genetic studies in MS comprising a total of 15,317 cases and 29,529 controls.  The distribution 
of nominally significant loci at the gene-level matched the patterns of extended linkage 
disequilibrium in regions of interest. We found that products of genome-wide significantly 
associated genes are more likely to interact physically, and belong to the same or related 
pathways. We next searched for sub-networks (modules) of genes (proteins) enriched in 
nominally associated loci within each study and identified those modules in common between 
the two studies. We demonstrate that these modules are more likely to contain genes with 
bona-fide susceptibility variants and, in addition, identify several high-confidence candidates 
(including BCL10, CD48, REL, TRAF3 and TEC). Protein interaction network-based pathway 
analysis is a powerful approach to gain further insights into the biology of associated genes and 
to prioritize candidates for subsequent genetic studies of complex traits.  
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INTRODUCTION 
Genome-wide association studies (GWAS) are a powerful approach to examine the genetic 
components of complex diseases. A commonly utilized strategy in the analysis of GWAS 
involves the evaluation of individual markers using a genome-wide significance cutoff P value of 
5 x 10-8, under the assumption of independence among markers. This approach minimizes false 
discoveries and has indeed enjoyed remarkable success, uncovering  multiple variants 
associated with complex diseases and traits 1. However, the very small fraction of both the 
heritable component and the population disease burden explained by the polymorphisms 
identified in most GWAS initiatives suggest that a sizable proportion of risk alleles are still being 
missed by this strategy 2; 3. It is likely that alternative analysis approaches to GWAS data that 
focus on the combined effects of many loci, each making a small contribution to overall disease 
susceptibility, may reveal insights into the genetic basis of common chronic disease. An 
interesting study by the International Schizophrenia Consortium proved that by analyzing 
markers en-masse with a significance threshold as modest as 0.1, important information can be 
obtained from a well powered GWAS 4. More recently, a similar approach was applied to 
multiple sclerosis (MS [MIM 126200]) using data from two independent GWAS and implicated 
thousands of markers with p<0.2, suggesting a clear polygenic model of disease susceptibility 5.  
Furthermore, it is highly probable that univariate, single-locus analysis results contain 
informative trends that, when viewed in the contexts of genetic networks and fundamental 
molecular pathways, can expose aspects of the polygenic basis of disease susceptibility. A 
number of efforts to study biologically meaningful combinations of genes and markers have 
been reported, ranging from the simple computation of over-representation of associated loci 
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in gene ontology or KEGG pathways 6, up to more elaborated methods using gene sets 
enrichment 7 8 9; 10. An advanced modification of these methods incorporates the use of protein 
interaction networks and searches for sub-networks (modules) enriched within the associated 
genes. This approach increases the prior probability of an association by merging statistical 
evidence of marker/gene association with physical evidence of interaction among those gene 
products (proteins). Several versions of this approach have been reported in multiple complex 
traits including autoimmune and neurological diseases 11-18_ENREF_11.  
MS is a common inflammatory disease of the central nervous system with a well-documented 
genetic component 19; 20. Seven moderately powered but independent GWAS and one meta-
analysis were reported between 2007 and 2011, altogether identifying 23 non-HLA associated 
loci 21-27. Later, a meta-analysis (referred to as meta2.5 in this study) including most of these 
samples was carried out, and evidence of association for 2 additional loci was reported 28. In 
collaboration with the Wellcome Trust Case-Control Consortium 2 (WTCCC2), the International 
MS Genetics Consortium (IMSGC) recently completed the largest GWAS in MS to date (referred 
to as WTCCC2 in this study) and raised the number of non-HLA genetic loci associated with this 
disease to 57 29.  
Despite this notable progress, our understanding of MS genetics remains incomplete. To further 
unravel the missing heritability in MS, we conducted a protein interaction network-based 
pathway analysis (PINBPA) of these two largely independent GWAS datasets in MS (meta 2.5 
and WTCCC2), totaling more than 15,000 cases and almost 30,000 controls. We found that 
proteins encoded by genes harboring risk variants are more likely to interact, and take part of 
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the same or related pathways. Furthermore,  additional susceptibility variants were identified 
through this approach.  
SUBJECTS AND METHODS 
Datasets and preprocessing 
P-values for all tested SNPs (summary-level data) were collected for two MS datasets (WTCCC2 
and meta2.5) and one each for type 1 diabetes (T1D [MIM 222100]), rheumatoid arthritis (RA 
[180300]), Crohn’s disease (CD [MIM 266600]), coronary artery disease (CAD [MIM 611139]), 
hypertension (HT [MIM 145500]) and type 2 diabetes (T2D [MIM 125853]) (all from WTCCC1) 30 
to be used as  control. All datasets are composed of samples of European descent. The WTCCC2 
MS dataset 29 consists of 9,772 cases and 17,376 controls analyzed with the Illumina Human 
660-Quad and Illumina 1.2M platforms. The meta2.5 dataset is an imputation-based meta-
analysis with 2,529,394 unique SNPs 28 and includes all previously published GWAS in MS 
(totaling 5,545 cases and 12,153 controls) with minimum overlap (less than 10%) of cases with 
WTCCC2. Thus, these two datasets are considered independent in the context of the present 
study. Supplementary Table 1 summarizes details for each study used in this work. In order to 
enrich for potentially functional variants, each dataset was filtered so as to keep only those 
SNPs which were non-synonymous and potentially deleterious (classified as either probably or 
possibly damaging by POLYPHEN231) , or located in 5’ or 3’ untranslated regulatory regions 
(UTR), transcription factor binding sites (TFBS), or histone binding sites. To further reduce the 
number of redundant SNPs we eliminated those that were in close LD (R2 > 0.9). 
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 All data used in this manuscript was obtained following procedures in accordance with the 
ethical standards of the responsible committees on human experimentation (institutional and 
national) and proper informed consent was obtained. 
Computing gene-wise p-values and association blocks 
Since this study examines the functional relationships of genes and proteins, we needed to 
consider gene-level significance. To that end, we used VEGAS, a previously described method to 
convert individual SNP into gene-wise p-values 32. VEGAS assigns SNPs to each of 17,787 
autosomal genes according to positions on the UCSC Genome Browser hg18 assembly. In order 
to capture regulatory regions and SNPs in LD, gene boundaries are defined as 50 kb beyond the 
5′ and 3′ UTRs of each gene. VEGAS takes into account linkage disequilibrium (LD) patterns 
between markers within a gene by using Monte-Carlo simulations from the multivariate normal 
distribution based on the LD structure of a set of reference individuals (the HapMap2 CEU 
population). In VEGAS, the number of simulations per gene is determined adaptively. In the first 
stage, 103 simulations are performed. If the resulting empirical p value is less than 0.1, 104 
simulations are then performed. If the empirical p value from 104 simulations is less than 0.001, 
the program will perform 106 simulations. At each stage, the simulations are mutually exclusive. 
For computational reasons, if the empirical p value is 0, then no more simulations will be 
performed. An empirical p value of 0 from 106 simulations can be interpreted as p < 10−6, which 
exceeds a Bonferroni-corrected threshold of p < 2.8 × 10−6 (≈0.05/17,787; this threshold is likely 
to be conservative given the overlap between genes).  
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We defined association blocks as those groups of sequential genes with p-value < 0.05. A 
block_id was assigned to each association block along the genome for each study. 
 
Protein interaction network-based pathway analysis (PINBPA)  
We downloaded the entire iRefIndex database, a collection of 15 human protein interaction 
sets from different sources and computed the union dataset. This set comprised more than 
400,000 interactions among ~25,000 proteins. However, many of these interactions were either 
predicted or backed up by a single experiment (i.e. a single publication). In order to minimize 
the rate of false positives, we then filtered this large network to keep only those interactions 
that were described in at least two independent publications. This resulted in a network of 
8,960 proteins (nodes) and 27,724 interactions (edges). We used this high-confidence network 
for all subsequent analyses. The network was uploaded into Cytoscape 2.8.2 and annotated 
with genomic position, and gene-wise p-value, block_id and bona-fide genes (loaded as node 
attributes) for all studies analyzed. To avoid the complexity of the HLA region, p-values for 
genes mapping to the 6p21.3 region were not included as attributes. However, the nodes 
corresponding to those genes were left in the network, as they may still participate in relevant 
sub-networks with other significant genes.  
For each dataset, significant first-order interactions were computed by filtering the main 
network so as to keep only those genes (proteins) with VEGAS p-values <0.05. Then, the 
number of resulting nodes, edges and size of the largest connected component were computed 
within Cytoscape. To evaluate the likelihood that these numbers were obtained by chance (as a 
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consequence of the sheer number of interactions), we computed 1,000 simulations assigning p-
values at random from the same network and creating sub-networks of similar size.  These 
simulations were used as background to estimate the significance of the sub-networks obtained 
with the real gene-wise p-values.  
We then used the program (plugin) jActiveModules to conduct searches of sub-networks that 
are enriched in (but not necessarily composed of) genes with significant p-values. Although 
jActiveModules was originally designed to discover “active” sub-networks by evaluating 
network connectedness among differentially expressed transcripts, we adapted it to take 
association p-values instead 33. jActiveModules starts by converting each gene p-value into a z-
score by using the inverse normal cumulative distribution function (CDF). Then an aggregate z-
score is produced (zA) for an entire sub-network A of k genes, by summing the zi over all genes 
in the sub-network
1
 A i
i A
Z Z
k 
   . 
In order to properly capture the connection between genetic association and network topology, 
the probability of obtaining a given zA score by chance must be evaluated. This is accomplished 
by randomly samples gene sets of size k using a Monte Carlo approach, computing their zA 
scores, and then use these to derive estimates for the score mean k and standard deviation k 
for each k. Because the means and standard deviation are expected to be a smooth function of 
k, noise in the Monte Carlo estimates could be reduced by using a sliding window average. Thus 
the corrected sub-network score SA is 
( )A k
A
k
Z
S



 . We took an SA>3 as evidence of a 
biologically active sub-network. 
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Gene ontology and cell-specific expression of candidate genes 
To evaluate the biological relevance of the 79 genes described in Table 2, we conducted a gene 
ontology analysis (Biological process FAT set) using DAVID 34 with the following parameters: 
Similarity term overlap = 10, Similarity threshold = 0.50, Initial group membership = 5, Final 
group membership = 3, Multiple linkage threshold = 0.50 and EASE = 0.01. For pathways, we 
used the KEGG set and default parameters.  
Cell-specific expression was assessed using the Gene enrichment profiler tool35. This tool 
computes the expression and enrichment of any set of query genes based on a reference set 
obtained from 126 normal tissues and cell types (represented by 557 microarrays).  
Additional analysis and plots were performed using the R statistical package.  
Domain knowledge score (DKS) 
To prioritize unreported associations, we used a custom tool named domain knowledge score 
(DKS). DKS was programmed in R and works by performing sequential automated PubMed 
searches with each gene from a custom list and any combination of search terms. In this article, 
we combined each gene symbol of interest with the terms ‘multiple sclerosis’ OR 
‘inflammation’ OR ‘immunity’. In order to also capture older articles that may refer to outdated 
gene identifications, the tool also searches for all synonyms and aliases within a specific 
species. The score each gene gets is simply the number of PubMed articles (excluding reviews) 
retrieved with the input search terms. The DKS tool is available upon request. 
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RESULTS 
Here we describe a multi-analytical approach to integrate two large genomic datasets in MS 
(Supplementary Figure 1). Through this approach we merge statistical evidence of association 
with physical evidence of interaction at the protein level to identify associated loci and highlight 
functional pathways involved in disease susceptibility. 
Nominal gene-level associations cluster into blocks 
Individual SNP-wise summary-level data from two largely independent GWAS in MS was utilized 
to compute gene-level p-values using VEGAS 32. The first of these two studies comprised 9,772 
cases and 17,376 controls and was recently published by the International MS genetics 
consortium (IMSGC) and the Wellcome Trust Case Control Consortium (WTCCC2) 2 29. The 
second study is a meta-analysis encompassing all previous GWAS studies in MS, including a 
total of 5,545 cases and 12,153 controls 28. In order to maximize the chance that variants had a 
functional impact on the encoded protein, we selected the subset of 137,457 SNPs which were 
non-synonymous and potentially deleterious (classified as either probably or possibly damaging 
by POLYPHEN2), or located in 5’ or 3’ untranslated regulatory regions (UTR), transcription factor 
binding sites (TFBS), or histone binding sites. VEGAS computes gene-wise p-values by taking 
into account relative genomic position, number of SNPs within a gene and patterns of LD for 
the appropriate ethnic background. An adaptive simulation strategy is used to calculate an 
empirical gene-based p-value for each annotated gene, which defines p< 2.8 x 10-6 as 
Bonferroni significant. Because our main hypothesis states that even modestly associated genes 
may participate in biologically plausible pathways, we considered all genes with VEGAS p < 0.05. 
A Manhattan plot visualization of both datasets at the gene-level denotes the presence of 
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peaks of association, similar to those observed with SNP-level data (Figure 1). The distribution 
of nominally significant loci at the gene-level largely replicated between the studies (see 
example in gray box in Figure 1) and closely matched the patterns of extended linkage 
disequilibrium previously observed in regions of interest. Specifically, 665 association blocks 
containing 1,997 genes were identified for the WTCCC2 dataset, and 612 blocks containing 
1,707 genes for the meta2.5 dataset. Of these, 625 genes overlapped, representing a much 
higher than expected proportion (4.8-fold enrichment) compared to what would be expected 
by chance (2 test, p < 2.2 10-16). Notably, association blocks defined in this way closely match 
the boundaries of the association regions for the 57 MS associated loci recently reported by the 
IMSGC 29, defined by extending a fixed genetic distance (0.25cM) from the lead SNP and from 
there to the closest recombination hot-spot from HapMap2. The overlap between studies was 
still significant after excluding genes from the MHC and from blocks implicated by the 57 
WTCCC2 loci and the 2 additional meta2.5 associated SNPs. In this filtered set, we found 
nominal association in 557 blocks (1471 genes) from WTCCC2 and 530 (1298 genes) from 
meta2.5 with an overlap of 271 genes (3.2-fold enrichment, Fisher’s exact p <2.2 10-16). 
 
Protein network-based pathway analysis 
We next sought to identify additional MS susceptibility loci by combining statistical evidence of 
gene association with physical evidence of interaction of their respective gene products using a 
curated human protein interaction network (PIN) dataset consisting of 8,960 proteins (nodes) 
and 27,724 interactions (edges) (see Methods). All subsequent experiments were performed 
13 | P a g e  
 
using Cytoscape, an open-source, and extensible network visualization and analysis tool 36. 
When we extracted the nodes with p-values < 0.05, sub-networks of 838 nodes (401 edges) and 
761 nodes (304 edges) were generated for the WTCCC2 and meta2.5 datasets, respectively (we 
refer to these as first-order networks). Given that neighboring genes have been shown to be 
functionally related and thus more likely to interact 18; 37, we repeated this experiment ensuring 
that only one gene per block was extracted from the main network. This resulted in first-order 
networks of 462 nodes (183 edges) for WTCCC2 and of 414 nodes (147 edges) for the meta2.5 
dataset. Both sub-networks were more connected than would be expected by chance, as 
demonstrated by a simulation experiment in which 1,000 networks of similar size were 
extracted from the same PIN at random (Figure 2). Of the other datasets used as controls T1D, 
CD and RA also produced highly connected sub-networks (Figure 2A). In each case, sub-
networks were composed of a large connected component and several smaller networks or 
isolated nodes (singletons). When first-order networks were computed using more significant 
p-value thresholds, most diseases showed more connections than expected (Supplementary 
Figure 2). We also tested whether the size of the main component was higher than what it 
would be expected by chance (given the number of edges in the first-order network) and 
observed that less than 1% of random networks resulted in larger connected components than 
those obtained for WTCCC2, meta 2.5 and CD datasets. Approximately 10% of random 
networks resulted in connected components of the size of those generated by HT and RA 
(Figure 2B). Again,  when first-order networks were computed using more significant p-value 
thresholds, most diseases showed larger connected components than expected 
(Supplementary Figure 3). The higher than expected first-order interactions and size of the 
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main connected component of these networks suggests a biologically plausible mechanism by 
which these gene sets coordinately affect cellular behavior.    
Given the small-world topology of the human protein interactome, it is possible that a few 
highly connected nodes (hubs) bring together several associated genes, even though the hubs 
themselves are not associated, thus defining biologically associated modules.  To explore this 
possibility, we conducted searches for sub-networks enriched in significant genes using jActive 
modules, a Cytoscape plugin based on a greedy heuristic algorithm with internal cross-
validation 33. Fifteen significant and minimally overlapping modules of sizes 5-200 were 
identified for the WTCCC2 dataset.  Similarly, 16 significant and minimally overlapping modules 
of sizes 5-189 were identified for the meta2.5 dataset (Table 1). We next computed the union 
of all modules within each dataset, resulting in a single connected network of 464 nodes and 
820 edges for WTCCC2 and another of 605 nodes and 1,031 edges for meta2.5. Finally, we 
computed the intersection of these two networks, which yielded 118 nodes and 95 edges. Of 
these, 88 genes were arranged in 13 networks of sizes 2-27, while the remaining 30 genes 
remained as singletons (Figure 3). We concentrated on the 88 genes arranged in networks as 
these genes and the connections among them were independently identified in both MS 
studies, and as such, we hypothesized these would have higher potential to include bona-fide 
susceptibility loci. Of these 88 genes, 54 had nominally significant p-values in both WTCCC2 and 
meta2.5 studies (v-shaped nodes in Figure 3), while the remaining 34 had significant p-values in 
only one or neither study. These 54 genes are of highest importance to our approach since they 
have significant p-values in both studies, and they were identified as components of significant 
networks in both studies as well. Notably, 30 of these genes contain either bona-fide 
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susceptibility variants (n=13), or are located within bone-fide associated regions (n=17)  (Table 
2, Figure 4), thus representing a specificity of 56% (Supplementary Table 2 lists all blocks 
harboring genes with bona-fide susceptibility variants and allows comparison of block structure 
from WTCCC2 and meta 2.5). Considering that only 34 of the 57 MS susceptibility loci identified 
to date are represented in the PIN, this approach was able to identify bona-fide MS loci with a 
sensitivity of 88%. Although an independent replication is warranted to firmly establish 
whether the remaining 24 genes are indeed associated, the high recall observed using the 
network-based approach lends support to their involvement in MS susceptibility 
(Supplementary Table 3 lists the complete block structure of each of these candidates in both 
WTCCC2 and meta 2.5 studies).  
When we explored the 30 singleton genes in the intersection network, we found that 26 of 
them had nominally significant p-values in both studies (Table 2, bold entries). Although these 
genes ended up as singletons in the intersection network, each of them was part of a 
connected network in either the WTCCC2 or meta 2.5 individual studies. Therefore, we also 
evaluated to what extent these genes (significant in both studies, but participating in networks 
in only one of them), included bona-fide MS susceptibility loci. Of these 26 genes, 12 either 
contain bona-fide susceptibility variants (n=3) or are located within bone-fide associated 
regions (n=9), representing a specificity of 46% and a sensitivity of 35% (Table 1, Figure 4).  
As a control, we also evaluated the recall potential of the 154 genes with nominally significant 
p-values in both studies, but that were not found in networks. Only 13 of them (8%) were bona-
fide MS genes and 26 (17%) were located within bona-fide MS blocks. The remaining 115 (75%) 
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remained  potential(non-validated) associations (Figure 4). These findings represent a 
sensitivity of 68%, and a specificity of 25%. 
Altogether, these results suggest that even nominally significant genes, if replicated in more 
than one study, represent a select list of candidates for further analysis. However, in the 
absence of any additional evidence the chances of discovering genuine associations among 
these genes are still hampered by a significant proportion of false positives. These probabilities 
are significantly increased when considering those genes that, in addition to showing 
(nominally) significant associations also participate in interaction networks in at least one study. 
The best results, nonetheless, were obtained when nominally significant genes were also 
identified as part of the same interaction network in both studies.  
The analysis of other diseases from WTCCC1 used as control also support this interpretation. In 
those datasets, the average sensitivity was 42.3% and the average specificity was 8.3%. 
Notably, CD yielded a sensitivity of 88% (the same obtained for MS), albeit with a much more 
modest specificity of 16% (compared with 56% for MS). The main factors contributing to the 
significantly better performance of the MS datasets were most likely their size and the 
availability of a replication dataset.  
 
Biological significance of associated and candidate genes in MS 
To explore the biological significance of the genes with either confirmed or suspected role in 
MS susceptibility (described in Table 2) we conducted a gene ontology (GO) and pathway 
analysis using DAVID. Among the 79 genes in these lists, GO analysis (Biological process) 
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identified three main categories as significantly enriched: leukocyte activation (enrichment 
score=9, lead category FDR-corrected p-value=1.3 x 10-8), apoptosis (enrichment score=6.16, 
lead category FDR-corrected p-value=2.2 x 10-6) and positive regulation of macromolecule 
metabolic process (enrichment score=5.86, lead category FDR-corrected p-value=4.7 x 10-8). 
When KEGG pathways were evaluated, JAK-STAT signaling pathway (enrichment score=3.47, 
lead category FDR-corrected p-value=1.4 x 10-5), Acute myeloid leukemia (enrichment 
score=2.22, lead category FDR-corrected p-value=5.9 x 10-3), and T cell receptor signaling 
(enrichment score=1.63, lead category FDR-corrected p-value=0.01) were significantly enriched.  
We also computed the tissue specificity of these genes using the gene enrichment profiler 
utility (see methods). Approximately two thirds of these genes were highly expressed in 
immune related cell types, and about half in the CNS (Supplementary Figure 4, red or black 
color).  However, enrichment maps overwhelmingly highlight immune related cell types 
(Supplementary Figure 5). Since only three genes (PDE4A [MIM 600126], RAB3A [MIM 179490] 
and VAMP1 [MIM 185880]) appear to be specifically enriched in the CNS, we were unable to 
confirm our earlier observation that neural pathways were involved in the susceptibility to 
MS12.  
Finally, we used a combination of gene-level statistical significance and text mining (DKS, 
domain knowledge score, see Methods) to highlight some of the previously unreported 
candidate associations emerging from the analysis (Table 2). Based on stringent criteria (p<0.01 
in both studies and DKS >50) 5 genes were identified as the most plausible candidates. B-cell 
lymphoma 10 (BCL10 [MIM 603517]) (DKS=62), CD48 [MIM 109530] (also known as B cell 
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membrane protein) (DKS=83), v-rel reticuloendotheliosis viral oncogene homolog (REL [MIM 
164910]) (DKS=630), TNF receptor-associated factor 3 (TRAF3 [MIM 601896]) (DKS=60), and the 
protein tyrosine kinase TEC [MIM 600583] (DKS=230). Although it is not possible to 
unequivocally implicate any of these candidates in MS susceptibility, in the absence of 
experimental functional data the combined strategy described here provides a more 
comprehensive interpretation of these associations.  
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DISCUSSION 
One plausible cause for the manifestation of complex diseases is the genetic alteration in the 
function of specific biological pathways through the presence of multiple variants in different 
genes (each contributing a modest amount to disease predisposition) and ultimately leading to 
disruptions in normal biological processes. We have found that even nominally associated 
genes (i.e. gene-level data) were not scattered randomly across the genome, but rather 
agglomerated into clusters or blocks of association, in a similar fashion that regional association 
plots show for SNP-level data. In fact, the gene-wise association blocks defined in this study and 
the critical regions defined in the original WTCCC2 publication are remarkably similar (see 
supplementary Table 2). It is noteworthy that any other gene-wise p-value threshold would 
have resulted in a different arrangement of genes into blocks, likely smaller and fewer. Thus, 
the close agreement in association block structure and size supports our choice of nominal p-
value as a threshold for the remainder of the study. Furthermore, this finding has important 
implications, as it indicates that our strategy of selecting potentially functional SNPs and 
nominally significant genes produces comparable results to the more established approach 
utilized in our previous study of extending a fixed genetic distance from the lead SNP, and from 
there to the next recombination hot-spot 29. This also suggests that in most regions, the 
extended patterns of LD would determine the upper limit of resolution of this approach, except 
in cases in which a variant with obvious functional consequence is identified within these 
regions.  
We demonstrated that truly associated genes are more likely to be connected in the PIN. By 
extension, we hypothesized that significant sub-networks (enriched in nominally significant 
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genes) would contain genes which are more likely to be genuinely associated. Assuming that 
107 common single nucleotide variants exist in the human genome and that 100 of them are 
truly associated with MS, the prior probability of finding an association by chance is 100,000:1 
against (10-5). Theoretical calculations have suggested that the cutoff of statistical significance 
required to yield an association that is more likely true than false, is directly related to its 
sample size (power) 38. For example, under these assumptions, a p-value of 10-6 is predicted to 
identify an association that is 10 times more likely to be true than false for a study of 10,000 
cases and 10,000 controls, but equally likely to be true or false if the size of the study is 2,000 
cases and 2,000 controls. For a study with 1,000 cases and 1,000 controls, that same threshold 
p-value will identify associations which are 10 times more likely to be false than true. These 
theoretical estimates have also showed that if the prior probability of an association is 
increased, for example, by two orders of magnitude (from 10-5 to 10-3), the p-value threshold 
generating the same level of confidence in a result can be reduced by roughly the same 
magnitude (from 10-6 to 10-4). It follows that increasing the prior probability is a meaningful way 
to increase the power of detecting bona-fide associations in a study of a given size. Several 
ways to increase the prior probability of an association exist. In this study we have aimed at 
increasing the prior odds by using a 3-way strategy. First, we conducted our analysis only using 
functional or potentially functional SNPs. Since non-synonymous coding variants and variants in 
regulatory regions or splice sites are more likely to have a functional effect than variants in 
silent non-coding regions concentrating analysis on these more functional relevant variants is a 
reasonable strategy to improve the prior odds 39. Second we computed gene-wise p-values, 
thus significantly reducing the number of possible tests by ~8-fold (from 137,457 to 17,787). 
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Third we prioritized candidates that were arranged in interaction networks, which as shown 
above, increases the likelihood of finding true associations.  
Altogether, this strategy (similar in concept to the genomic convergence paradigm previously 
described 40) is likely to increase the priors, although it is not possible to determine exactly by 
which magnitude. The fact that recall power of the two MS datasets was large (AUC of 0.95 and 
0.88), further encouraged us to evaluate genes with an even modest statistical evidence of 
association. Therefore, we took a liberal approach and considered every gene-level association 
with a nominal p-value of 0.05. In support of this strategy, we found that the overlap of 
nominally significant genes between WTCCC2 (n=1,997) and meta2.5 (n=1,707) studies was 
625, a 6-fold increase of what it would be expected by chance (Fisher’s exact p-value <10-16).  
An important finding of this study is that nominally associated genes are more connected in the 
PIN than what it would be expected by chance. This provides further evidence that in well 
powered studies, the 3-way strategy followed here (selection of potentially functional SNPs, 
analyzing nominal gene-level significance and studying genes in the context of biological 
networks) maximizes the potential of finding bona-fide associations. Furthermore, this 
approach may highlight the importance of a different gene than the one originally selected 
within a GWAS associated block. For example, a non-synonymous SNP (rs3748816) in 
membrane metalloendopeptidase-like 1 (MMEL1) was originally identified as a susceptibility 
gene though a screen of candidate genes in 3,444 affecteds and 2,595 controls showing a p-
value of 3.54 x 10-6 (odds ratio=1.16) 41. This association was further replicated by the WTCCC2 
GWAS with a p-value of 2.25 10-13. Its p-value in meta 2.5 was 2.81 10-5. However, given the 
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extensive LD in this region, it is not possible to exclude the possibility that other genes within 
this block are instead associated with MS. In addition to MMEL1, genes in this association block 
include PLCH2 [MIM612836], PANK4 [MIM 606162], HES5 [MIM 607348], TNFRSF14 [MIM  
602746] and C1orf93. This region was also identified in the present study with a block p-value 
of 10-7 (genome-wide significant) in WTCCC2 and 1.49 10-4 in meta2.5 (Supplementary Table 2). 
However, the only gene product from this block that appeared in the final intersection network 
was TNFRSF14, with direct interactions with TRAF2 (not significant) and TRAF3 (p-values of 1.3 
10-3 and 1.13 10-3 in WTCCC2 and meta2.5 respectively)(Figure 4). Furthermore, TNFRSF14 is a 
ligand of TNFSF14, one of the 57 susceptibility loci identified by the WTCCC2 GWAS. 
Interestingly, although physically within MMEL1, rs3748816 was mapped to TNFRSF14 by 
VEGAS in WTCCC2 and to both genes in meta2.5, likely due to its high LD. Altogether, and in the 
absence of additional functional experimental data, these results provide more evidence to 
implicate variants in TNFRSF14 than MMEL1 as an MS susceptibility locus. Ultimately, however, 
experimental evidence will be needed to determine this with precision.  
Another example is the association block containing VCAM1 [MIM 192225], EXTL2 [MIM 
602411], SLC30A7 [MIM 611149], DPH5 [MIM 611075], and S1PR1 [MIM 601974]. Although 
VCAM has been selected as the most likely associated gene from this block (presumably due to 
its function in cell adhesion), the WTCCC2 regional association plot shows that this gene falls 
slightly outside the block, and the most significant functional SNP maps to SLC30A7. In this 
study, however, the block extends to include VCAM1 and S1PR1. Furthermore, the only gene 
that is significant in both WTCCC2 and meta2.5 and shows in the final intersection network is 
S1PR1 (sphingosine-1-phosphate receptor 1) (Figure 4). This is of relevance, as S1PR1 is the 
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target of the disease modifying therapy Fingolimod. Again, further experimental approaches 
are warranted to determine which are the functionally relevant associations in each of these 
loci.  
We acknowledge that the lack of an independent replication is a limitation when predicting 
new associations. However, the successful identification of several bona-fide susceptibility 
variant-containing genes, the prioritization of different genes within a known association block 
and the proposal of new candidate associations are valuable outcomes only achieved by 
integration of different sources of evidence. Results from this approach contribute to firmly 
establish that genes and pathways involved in the immune response are the major drivers of 
MS risk.  
 
Supplemental Data description: 
 
Supplementary Figure 1. Strategy 
Supplementary Figure 2. Total number of edges as a function of the number of significant 
number of genes at different significance thresholds 
Supplementary Figure 3. Size of the largest connected component as a function of the total 
number of edges in the first-order networks at different thresholds of significance 
Supplementary Figure 4. Transcript expression heatmap. 
Supplementary Figure 5. Transcript enrichment heatmap  
Supplementary Table 1. Study details 
Supplementary Table 2. Prioritization of candidate genes within a block (Functional mapping) 
Supplementary Table 3. Previously unreported candidate genes 
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Figure Legends 
 
 
Figure 1. Double Manhattan plot.  
A Manhattan plot showing the gene-level p-values of both GWAS used in this study. Gene-level 
p-values from WTCCC2 are displayed at the top and those corresponding to meta2.5 at the 
bottom. A region in Chromosome 1 is enlarged to show detailed block structure. Blocks were 
defined as groups of contiguous genes with p-value of ≤ 0.05 (grayed area). The individual p-
value of each gene is displayed as a colored circle ranging from green (not significant) to yellow 
to red (most significant). Note that the two plots are largely specular, denoting overall 
replication (see text).  
 
Figure 2. Connectedness of first-order interaction networks. 
The number of connections among significant genes were evaluated in the background of 1,000 
random simulations (See text). A. The total number of edges was plotted as a function of the 
number of significant genes for each study. B. The size of the largest connected component is 
plotted as a function of the total number of edges. The colored lines represent 50th (green), 90th 
(yellow), 95th (orange) and 99th (red) percentiles obtained through simulations with random set 
of genes of similar size.  
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Figure 3. Intersection network.  
Of the 118 nodes obtained by intersecting the resulting networks from each independent study, 
88 were arranged in 13 sub-networks (ranging in size from 2 to 27) and 30 nodes remained 
isolated. Each node represents a gene product and each edge represents an experimental 
physical interaction reported in at least two independent publications. Thus, an edge is only 
displayed if the same interactions were identified in both studies. Isolated nodes in this 
representation may still have interactions within each of the studies, but they have not been 
preserved in both. White nodes are not significant. A color scale (yellow to red) denotes the 
significance of each node in WTCCC2. V-shaped nodes have nominal significant p-values in both 
studies. Nodes With a yellow outline denote genes containing bona-fide MS susceptibility 
variants. A different background color was chosen to highlight each of the 6 sub-networks with 
size ≥ 3 (sub-networks of size = 2 were grouped under the same background).  
 
Figure 4. Proportion of validated discoveries using a network vs. a non-network approach  
Of the 118 genes in the intersection network 88 genes were arranged in 13 sub-networks sizes 
2-27. Of those, 54 genes were nominally significant in both studies. 55% of these genes were 
either bona-fide MS genes (24%) or fell into bona-fide MS blocks (31%). Of the 30 singletons 
from the 118 gene intersection network, 26 had significant p-values in both studies. 46% of 
these  were either bona-fide MS genes (11%) or fell into bona-fide MS blocks (35%). From the 
154 genes with significant p-values but not found in networks, only 25% were either bona-fide 
MS genes (8%) or fell into bona-fide MS blocks (17%).  
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Table 1. Gene-level significance, power,  and network characteristics of each GWAS 
Disease Number of 
nominally 
significant 
genes 
Area 
under 
ROC 
Size of 1st 
order 
interaction 
net (nodes-
edges) 
Number of 
sub-
networks 
(min-max 
size) 
Size of 
union net 
(nodes-
edges) 
Sensitivity 
(%) 
Specificity 
(%) 
MS 
(WTCCC2) 
1,996 0.95 838-401 15 (6-200) 464-820 88 
 
- 
56 
 
- 
MS 
(meta2.5) 
1,706 0.88 761-304 16 (5-189) 605-1031 
T1D 1,056 0.65 474-161 13 (5-170) 378-669 30 4.4 
T2D 913 0.71 405-74 8 (10-211) 332-562 34 17.0 
RA 937 0.66 360-68 16 (6-207) 347-632 12 1.7 
CD 997 0.72 469-116 15 (5-231) 449-1066 88 16.0 
CAD 831 0.60 393-75 15 (6-183) 299-491 52 8.3 
HT 813 0.64 349-40 13 (6-167) 355-500 38 2.6 
 
MS: multiple sclerosis [MIM 126200]; T1D: type 1 diabetes [MIM 222100]; T2D: type 2 diabetes [MIM 
125853]; RA: rheumatoid arthritis [MIM 180300]; CD: Crohn’s disease [MIM 266600]; CAD: coronary 
artery disease [MIM 607339]; HT: Hypertension [MIM 145500].   
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Table 2. Nominally significant genes in WTCCC2 and meta2.5 and arranged in networks in at least one study 
Bona-fide MS susceptibility loci Previously unreported (candidate) loci 
Gene Block    
Gene symbol p-value 
(WTCCC2) 
p-value 
(meta2.5) 
Gene symbol p-value 
(WTCCC2) 
p-value 
(meta2.5) 
Gene symbol p-value 
(WTCCC2) 
p-value 
(meta2.5) 
CD58 2E-05 1E-06 TNFRSF14 1E-07 0.00055 PHGDH 0.0008 0.00012 
MERTK 0.0026 0.01698 S1PR1
a
 0.0261 0.00992 ETS1 0.0122 0.02008 
IL12A 3E-05 0.00066 GOLGB1 1E-07 0.00197 TRAF3 0.0013 0.00113 
IL7R 0.0005 0.00137 KIF5A 0.0002 0.00337 BCL10 2E-05 0.00054 
IL12B 4E-06 1E-07 CIITA 1E-07 0.0129 CD48 9E-06 0.00902 
IL7 3E-05 0.00339 SOCS1 1E-07 2E-06 REL 0.0003 0.00047 
IL2RA 0.0015 0.00063 RBM17 1E-05 0.00271 C17orf57 0.0117 0.00259 
TNFRSF1A 1E-07 0.00019 SCNN1A 2E-06 0.00017 KPNB1 0.0002 1E-07 
STAT3 0.0001 0.00004 LTBR 2E-06 0.00061 CHERP 0.0018 1.6E-05 
MALT1 0.0002 0.00068 CD27 0.0003 0.0125 TEC 0.0007 0.00048 
CD40 0.0002 0.02198 VAMP1 0.0003 0.01662 CSF2 0.0112 0.00755 
MAPK1 5E-05 0.00063 STAT5A 0.0002 1.8E-05 IRF1 0.0036 0.01076 
SCO2 1E-05 0.00315 STAT5B 0.0349 0.00099 EIF3B 5E-05 0.03787 
VCAM1 0.0008 0.00917 CLTC 0.0066 0.00088 JAK2 0.01 0.01543 
33 | P a g e  
 
RGS1 5E-06 0.00076 KEAP1
b
 0.0019 0.03798 PAX5 0.0232 0.04573 
TNFSF14 0.0002 0.00452 PFDN4 0.0001 0.01813 RIC8A 0.0061 0.02786 
- - - TOP3B 0.0006 0.00695 NR1H3 0.0007 0.00472 
- - - BCL2L11 0.0005 0.00101 SART1 0.0001 0.00115 
- - - HCLS1 0.0035 0.0157 VPS33A 0.0091 0.00124 
- - - CDK4 1E-06 1.1E-05 MARK3 0.0066 9.6E-05 
- - - PITPNM2 0.0002 0.00133 FBF1 0.0232 0.00657 
- - - OGFOD2 0.0006 0.0032 PIK3R2 1E-07 0.01093 
- - - C3 0.0003 0.02719 PITPNB 0.0059 0.01738 
- - - PDE4A 1E-07 0.0048 BBC3 0.0006 0.01007 
- - - RTEL1 4E-05 0.00665 SLAMF1 0.008 0.0497 
- - - PPM1F 0.0006 0.00458 MORF4L1 0.0105 0.0022 
- - - - - - MED26 0.001 0.0002 
- - - - - - TXK 0.0002 0.00039 
- - - - - - IKZF1 0.0068 0.04215 
- - - - - - BMI1 0.01 0.0102 
- - - - - - PSMD13 0.0054 0.02084 
- - - - - - FOSL1 0.007 0.02244 
- - - - - - CLIP1 0.005 4.6E-05 
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- - - - - - ITGAX 0.0025 0.01925 
- - - - - - JUP 0.0306 0.01387 
- - - - - - DNAJC7 0.0069 0.01956 
- - - - - - RAB3A 1E-05 0.01381 
a
 Is significant but gene falls in a contiguous block. 
b
 Is significant but block in meta2.5 is smaller than in WTCCC2. Genes in bold are 
those with significant p-values in both studies but arranged as singletons in the intersection network from Figure 3 
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Supplementary Figure 1. Strategy 
 
 
Summary-level data from two independent studies in MS were used, along with that of 6 
diseases from the WTCCC1 study as controls. In the first step, SNPs with potentially functional 
consequences were selected. These included coding non-synonymous substitutions, and those 
mapping to 3’ or 5’ UTRs, and transcription factor or histone binding sites. Next, a gene-wise p-
value was obtained using VEGAS, and genes with a p-value of 0.05 were analyzed further. ROC 
curves were computed to evaluate the power of each study to identify all known susceptibility 
loci (bona-fide) to date. In the following step gene p-values were overlapped with a curated 
protein interaction network (See methods) and interactions among nominally significant genes 
(first-order) were computed. With the goal of discovering additional associations, a heuristic 
search for sub-networks enriched in significant genes was conducted using jActive modules 
within Cytoscape. All significant sub-networks within each independent study were merged and 
finally the intersection network was computed, resulting in 118 nodes which were analyzed in 
depth.  
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Supplementary Figure 2. Total number of edges as a function of the number of 
significant number of genes at different significance thresholds 
 
 
 
The total number of edges as a function of the number of significant number of genes at 
different significance thresholds is shown. At higher thresholds of significance (0.001) all 
diseases show more edges than expected by chance. As the significance drops, fewer studies 
(mostly those well powered) show this property. Notably, networks from WTCCC2 and meta2.5 
are clearly more connected than chance 
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Supplementary Figure 3. Size of the largest connected component as a 
function of the total number of edges in the first order networks at different 
thresholds of significance 
 
 
The size of the largest connected component as a function of the total number of edges in the 
first order networks at different thresholds of significance is shown. This Figure highlights that a 
large proportion of the total number of edges counts towards formation of the largest 
connected component of the first order interaction network. As expected, this is more evident 
at higher thresholds, but it is also true at 0.05 for WTCCC2 and meta2.5 
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Supplementary Figure 4. Transcript expression heatmap.  
 
 
Transcript expression with the 88 genes from the intersection network which were arranged in 
networks was computed using the Gene enrichment profiler tool 35. This approach computes 
the expression of all mapping transcripts in a user-initiated query in each of 126 normal tissues. 
Almost two-thirds of genes in this list are highly expressed in immune-related tissues and cell 
types. Almost half are also highly expressed in the CNS and other tissues. Colors correspond to 
the level of enrichment in each tissue (green = depleted, black = no enrichment, red = 
enriched). 
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Supplementary Figure 5. Transcript enrichment heatmap 
 
Transcript enrichment with the 88 genes from the intersection network which were arranged in 
networks was computed using the Gene enrichment profiler tool 35. This approach computes 
the enrichment of all mapping transcripts in a user-initiated query in each of 126 normal 
tissues. A significant proportion of genes in this list, are enriched in immune-related tissues and 
cell types (specifically B, T and myeloid cells). Three genes (PDE4EA, RAB3A and VAMP1) appear 
to be enriched in CNS tissues. Colors correspond to the level of enrichment in each tissue 
(green = depleted, black = no enrichment, red = enriched). 
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Supplementary Table 1.  
Supplementary Table 1. Study details  
Disease Number of cases Number of controls Reference 
MS (WTCCC2) 9,772 17,376 {Sawcer, 2011 #7199} 
MS (meta2.5) 5,545 12,153 {Patsopoulos, 2011 #6087} 
T1D 2000 3,0000 {WTCCC, 2007 #1670} 
T2D 2000 3,0000 {WTCCC, 2007 #1670} 
RA 2000 3,0000 {WTCCC, 2007 #1670} 
CD 2000 3,0000 {WTCCC, 2007 #1670} 
CAD 2000 3,0000 {WTCCC, 2007 #1670} 
HT 2000 3,0000 {WTCCC, 2007 #1670} 
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Supplementary Table 2. Prioritization of candidate genes within a block (Functional mapping) 
 
    WTCCC2 Meta2.5 
Gene Chr position nSNPs Test Pvalue Best.SNP SNP.pvalue block# 
block best 
pvalue nSNPs Test Pvalue Best.SNP SNP.pvalue 
block
# 
block best 
pvalue 
PLCH2 1 2397613 9 35.00558 0.0034 rs17373634 0.000274 1 0.0000001 NA NA NA NA NA NA NA 
PANK4 1 2429834 10 65.5516 6.90E-05 rs6667605 5.16E-07 1 0.0000001 10 23.06865 0.04864 rs6667605 0.000413 4 0.000149 
HES5 1 2450043 7 60.87558 1.70E-05 rs6667605 5.16E-07 1 0.0000001 7 20.72394 0.02821 rs6667605 0.000413 4 0.000149 
TNFRSF14 1 2479150 8 153.8989 1.00E-07 rs3748816 2.25E-13 1 0.0000001 8 51.5609 0.000551 rs3748816 2.81E-05 4 0.000149 
C1orf93 1 2508108 6 202.3974 1.00E-07 rs3890745 5.79E-14 1 0.0000001 6 59.12327 0.000149 rs3748816 2.81E-05 4 0.000149 
MMEL1 1 2511940 6 202.3974 1.00E-07 rs3890745 5.79E-14 1 0.0000001 6 59.12327 0.000158 rs3748816 2.81E-05 4 0.000149 
VCAM1 1 100957884 10 40.48064 0.000756 rs11586136 8.34E-06 32 0.0000001 10 28.67992 0.00917 rs2050471 0.002007 32 0.00917 
EXTL2 1 101110528 7 86.51482 1.00E-07 rs11809572 3.97E-09 32 0.0000001 7 22.15338 0.01564 rs12048904 0.000577 32 0.00917 
SLC30A7 1 101134265 13 225.9379 1.00E-07 rs11809572 3.97E-09 32 0.0000001 13 39.0039 0.02525 rs12048904 0.000577 32 0.00917 
DPH5 1 101227768 8 172.2086 1.00E-07 rs7521424 4.12E-09 32 0.0000001 8 20.38018 0.07685 rs7521424 0.03806 NA 0.07685 
S1PR1* 1 101474892 16 38.97881 0.02608 rs2031959 0.01244 32 0.0000001 16 47.31656 0.00992 rs4459133 0.001194 33 0.00992 
CD58 1 116858679 15 97.04105 1.60E-05 rs1335532 2.01E-09 35 0.0000001 15 113.3989 1.00E-06 rs1335532 1.51E-09 36 0.000001 
IGSF3 1 116918553 6 68.51176 1.00E-07 rs1335532 2.01E-09 35 0.0000001 6 71.22613 1.00E-06 rs1335532 1.51E-09 36 0.000001 
CD2 1 117098608 6 14.3167 0.04127 rs798037 0.01902 35 0.0000001 NA NA NA NA NA NA NA 
ACOXL 2 111206679 13 55.90904 0.0016 rs1439287 9.41E-05 93 0.000024 14 41.65543 0.01134 rs1837369 0.0007737 96 0.001007 
BCL2L11 2 111594961 18 122.7645 0.000528 rs1439287 9.41E-05 93 0.000024 18 110.5492 0.001007 rs9308742 0.0003182 96 0.001007 
ANAPC1 2 112243110 7 56.36742 2.40E-05 rs17174870 7.78E-06 93 0.000024 7 36.1738 0.001386 rs17174870 0.000391 96 0.001007 
MERTK 2 112372661 23 116.6903 0.0026 rs17174870 7.78E-06 93 0.000024 23 75.72197 0.01698 rs11884641 0.0002625 96 0.001007 
TMEM87B 2 112529284 14 57.90995 0.00158 rs11884641 1.37E-05 93 0.000024 NA NA NA NA NA NA NA 
SCHIP1 3 160474237 NA NA NA NA NA NA NA 34 85.7023 0.01683 rs7635938 0.004963 137 0.000657 
IL12A 3 161189322 14 102.9125 3.20E-05 rs2243123 3.68E-06 159 0.000032 14 73.1439 0.000657 rs7610160 2.07E-05 137 0.000657 
FBXO40 3 122794859 13 30.59088 0.03828 rs7153 0.000212 153 0.0000001 13 28.83312 0.04871 rs7153 0.001342 129 0.001069 
HCLS1 3 122832935 11 43.51908 0.00347 rs3732410 0.000172 153 0.0000001 11 33.69831 0.0157 rs7153 0.001342 129 0.001069 
GOLGB1 3 122864737 13 148.2947 1.00E-07 rs6808500 9.61E-08 153 0.0000001 14 66.21549 0.001969 rs7153 0.001342 129 0.001069 
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IQCB1 3 122971299 10 206.7136 1.00E-07 rs1920298 6.35E-08 153 0.0000001 11 68.01742 0.002043 rs1920298 0.000972 129 0.001069 
EAF2 3 123036723 10 170.883 1.00E-07 rs1920298 6.35E-08 153 0.0000001 11 57.20001 0.00271 rs1920298 0.000972 129 0.001069 
SLC15A2 3 123095976 9 91.98277 3.10E-05 rs4285028 3.70E-08 153 0.0000001 9 49.99358 0.00277 rs9289185 0.000415 129 0.001069 
ILDR1 3 123188859 12 91.78509 4.00E-06 rs4285028 3.70E-08 153 0.0000001 12 52.89139 0.001069 rs9289185 0.000415 129 0.001069 
CD86 3 123256910 11 70.89507 8.70E-05 rs9282641 1.54E-09 153 0.0000001 11 41.39866 0.00473 rs9282641 2.77E-05 129 0.001069 
CASR 3 123385219 NA NA NA NA NA NA NA 16 41.75711 0.01922 rs1979869 0.002792 129 0.001069 
SPEF2 5 35653745 14 80.14992 0.00019 rs11748781 0.00066 197 0.000118 15 59.49978 0.002249 rs931555 0.002935 181 0.000555 
IL7R 5 35892747 15 95.10324 0.000525 rs6897932 2.63E-06 197 0.000118 15 83.30192 0.00137 rs6897932 0.0002259 181 0.000555 
CAPSL 5 35940154 26 161.6188 0.000118 rs6897932 2.63E-06 197 0.000118 26 135.3675 0.000555 rs6897932 0.0002259 181 0.000555 
UGT3A1 5 35988966 16 81.84978 0.001044 rs1993879 9.52E-06 197 0.000118 16 64.1848 0.00474 rs860413 0.0003444 181 0.000555 
EBF1 5 158055500 26 69.06629 0.01174 rs10515789 0.00032 218 0.000003 NA NA NA NA NA NA NA 
RNF145 5 158516996 10 41.9753 0.0038 rs6556396 0.00947 218 0.000003 NA NA NA NA NA NA NA 
UBLCP1 5 158622666 7 65.14022 3.00E-06 rs2546890 2.74E-07 218 0.000003 8 79.78664 1E-07 rs2546890 7.95E-08 203 0.0000001 
IL12B 5 158674368 6 56.23183 4.00E-06 rs2546890 2.74E-07 218 0.000003 7 82.49851 1E-07 rs2546890 7.95E-08 203 0.0000001 
ALDH8A1 6 135280220 NA NA NA NA NA NA NA 10 47.16629 0.00167 rs9385708 8.06E-05 241 0.00167 
HBS1L 6 135323213 NA NA NA NA NA NA NA 16 58.98443 0.01571 rs12526072 0.009443 241 0.00167 
MYB # 6 135544145 12 77.80818 0.00077 rs9321490 5.81E-06 258 0.0000001 12 8.631174 0.536 rs2050019 0.04948 NA 0.536 
AHI1 6 135646816 9 195.2345 1.00E-07 rs11154801 1.53E-12 258 0.0000001 10 74.40884 0.000435 rs11154801 0.0001161 242 0.000435 
PKIA 8 79590890 10 40.70157 0.0141 rs11781853 0.00133 309 0.000033 10 117.5594 1.40E-05 rs10504676 1.38E-05 292 0.000014 
FAM164A 8 79740884 6 92.28494 3.60E-05 rs3736169 3.44E-05 309 0.000033 6 58.15676 0.001025 rs1384804 0.0004862 292 0.000014 
IL7 8 79807559 4 44.15623 3.30E-05 rs1441438 5.09E-05 309 0.000033 4 23.16013 0.00339 rs2369440 0.0007909 292 0.000014 
IL2RA 10 6093511 21 88.14574 0.00151 rs942201 2.58E-07 352 0.000014 21 100.1787 0.000627 rs11256497 5.91E-05 339 0.000627 
RBM17 10 6171012 19 145.3416 1.40E-05 rs942201 2.58E-07 352 0.000014 19 76.69935 0.00271 rs11256497 5.91E-05 339 0.000627 
PFKFB3 10 6284900 23 46.51204 0.0307 rs630204 0.00416 352 0.000014 23 46.20471 0.03232 rs11257741 0.00899 339 0.000627 
CD9 12 6179815 NA NA NA NA NA NA NA 16 58.56654 0.00934 rs2268016 0.003049 397 0.000132 
PLEKHG6 12 6289862 16 128.8267 1.00E-07 rs1800693 1.84E-10 419 0.0000001 18 87.19434 0.000132 rs1800693 1.41E-05 397 0.000132 
TNFRSF1A 12 6308183 16 129.4852 1.00E-07 rs1800693 1.84E-10 419 0.0000001 18 83.38418 0.000191 rs1800693 1.41E-05 397 0.000132 
SCNN1A 12 6326273 18 130.4958 2.00E-06 rs1800693 1.84E-10 419 0.0000001 20 85.58752 0.000167 rs1800693 1.41E-05 397 0.000132 
LTBR 12 6363617 14 95.2566 2.00E-06 rs1860545 1.60E-09 419 0.0000001 15 56.72396 0.000613 rs1860545 2.02E-05 397 0.000132 
CD27 12 6424311 18 100.4861 0.000306 rs2250246 0.001324 419 0.0000001 19 57.0711 0.0125 rs2286596 0.004386 397 0.000132 
TAPBPL 12 6431437 20 104.0096 0.000319 rs2250246 0.001324 419 0.0000001 21 57.9826 0.01617 rs2286596 0.004386 397 0.000132 
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VAMP1 12 6441664 20 104.0096 0.000326 rs2250246 0.001324 419 0.0000001 21 57.9826 0.01662 rs2286596 0.004386 397 0.000132 
MRPL51 12 6471576 22 110.7377 0.000489 rs2250246 0.001324 419 0.0000001 23 56.23403 0.03407 rs2286596 0.004386 397 0.000132 
NCAPD2 12 6473558 22 91.31248 0.001926 rs2532497 0.001606 419 0.0000001 NA NA NA NA NA NA NA 
GAPDH 12 6513917 12 38.71814 0.01675 rs1048402 0.004681 419 0.0000001 NA NA NA NA NA NA NA 
IFFO 12 6518954 12 38.71814 0.0159 rs1048402 0.004681 419 0.0000001 NA NA NA NA NA NA NA 
MBD6 12 56202925 5 20.63647 0.02781 rs11172254 1.76E-05 437 0.0000001 NA NA NA NA NA NA NA 
DCTN2 12 56210360 4 20.4288 0.01547 rs11172254 1.76E-05 437 0.0000001 NA NA NA NA NA NA NA 
KIF5A 12 56230113 10 66.86074 0.000154 rs10083154 3.45E-06 437 0.0000001 10 43.49829 0.00337 rs923828 0.0001923 409 0.000008 
PIP4K2C 12 56271323 7 64.86693 1.40E-05 rs10083154 3.45E-06 437 0.0000001 7 42.49269 0.00058 rs923828 0.0001923 409 0.000008 
DTX3 12 56284870 7 64.86693 1.40E-05 rs10083154 3.45E-06 437 0.0000001 7 42.49269 0.000658 rs923828 0.0001923 409 0.000008 
GEFT 12 56290229 7 64.86693 1.50E-05 rs10083154 3.45E-06 437 0.0000001 7 42.49269 0.000633 rs923828 0.0001923 409 0.000008 
SLC26A10 12 56299959 9 109.5714 2.00E-06 rs774890 1.93E-06 437 0.0000001 9 65.53958 0.000196 rs923828 0.0001923 409 0.000008 
B4GALNT1 12 56305817 9 110.5821 3.00E-06 rs774890 1.93E-06 437 0.0000001 9 72.28768 0.000151 rs923828 0.0001923 409 0.000008 
OS9 12 56374152 13 191.5272 1.00E-07 rs12368653 1.99E-07 437 0.0000001 12 124.6172 1.40E-05 rs2069502 1.53E-05 409 0.000008 
CENTG1 12 56405260 12 164.6265 3.00E-06 rs12368653 1.99E-07 437 0.0000001 11 120.2294 8.00E-06 rs2069502 1.53E-05 409 0.000008 
TSPAN31 12 56425050 10 144.7957 1.00E-06 rs12368653 1.99E-07 437 0.0000001 9 107.3298 2.30E-05 rs2069502 1.53E-05 409 0.000008 
CDK4 12 56428269 10 144.7957 1.00E-06 rs12368653 1.99E-07 437 0.0000001 9 107.3298 1.10E-05 rs2069502 1.53E-05 409 0.000008 
MARCH9 12 56435166 11 157.938 1.00E-07 rs12368653 1.99E-07 437 0.0000001 10 118.9335 1.40E-05 rs2069502 1.53E-05 409 0.000008 
CYP27B1 12 56442383 11 157.938 1.00E-06 rs12368653 1.99E-07 437 0.0000001 10 118.9335 1.40E-05 rs2069502 1.53E-05 409 0.000008 
METTL1 12 56448617 10 137.9894 3.00E-06 rs12368653 1.99E-07 437 0.0000001 10 118.9335 1.60E-05 rs2069502 1.53E-05 409 0.000008 
FAM119B 12 56452649 10 137.9894 5.00E-06 rs12368653 1.99E-07 437 0.0000001 10 118.9335 1.00E-05 rs2069502 1.53E-05 409 0.000008 
TSFM 12 56462802 9 138.4423 4.00E-06 rs12368653 1.99E-07 437 0.0000001 9 113.2646 1.40E-05 rs2069502 1.53E-05 409 0.000008 
AVIL 12 56477709 9 121.1612 6.00E-06 rs703842 4.76E-06 437 0.0000001 9 109.2607 1.30E-05 rs2069502 1.53E-05 409 0.000008 
CTDSP2 12 56499976 6 80.25052 7.00E-06 rs10877013 7.77E-06 437 0.0000001 6 70.66554 2.70E-05 rs2291617 1.56E-05 409 0.000008 
ABCB9 12 121979491 10 39.66879 0.00325 rs7296418 0.0001872 452 0.000227 11 31.52114 0.01559 rs937564 0.001011 429 0.00133 
OGFOD2 12 122025306 5 36.72044 0.000574 rs7296418 0.0001872 452 0.000227 6 29.8209 0.0032 rs937564 0.001011 429 0.00133 
ARL6IP4 12 122030832 4 35.86565 0.000398 rs7296418 0.0001872 452 0.000227 5 28.83928 0.00204 rs937564 0.001011 429 0.00133 
PITPNM2 12 122033979 11 103.7941 0.000227 rs949143 0.0001538 452 0.000227 12 82.85517 0.00133 rs1106240 0.00068 429 0.00133 
MPHOSPH9 12 122206898 9 85.02801 0.000316 rs949143 0.0001538 452 0.000227 9 64.62894 0.001723 rs1790098 0.000653 429 0.00133 
C12orf65 12 122283415 4 34.99708 0.000528 rs4460848 0.0002456 452 0.000227 4 17.49441 0.01664 rs4460848 0.008892 429 0.00133 
CDK2AP1 12 122311492 5 30.84473 0.002039 rs7304782 0.0005952 452 0.000227 5 19.05534 0.01919 rs1060105 0.003909 429 0.00133 
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SBNO1 12 122346407 5 19.0769 0.02449 rs1060105 0.002443 452 0.000227 NA NA NA NA NA NA NA 
SETD8 12 122434656 1 4.27311 0.03928 rs1662 0.03872 452 0.000227 NA NA NA NA NA NA NA 
RILPL2 12 122465888 1 4.27311 0.03768 rs1662 0.03872 452 0.000227 NA NA NA NA NA NA NA 
U1SNRNPBP 12 122508603 1 4.27311 0.03892 rs1662 0.03872 452 0.000227 NA NA NA NA NA NA NA 
CIITA 16 10878555 16 161.3609 1.00E-07 rs1035089 5.27E-13 508 0.0000001 16 43.75733 0.0129 rs1035089 0.004249 486 0.000001 
DEXI 16 10930248 16 237.0363 1.00E-07 rs1035089 5.27E-13 508 0.0000001 16 59.22137 0.0046 rs7403919 0.001804 486 0.000001 
CLEC16A 16 10945942 57 1271.805 1.00E-07 rs7200786 6.30E-14 508 0.0000001 57 442.8161 3.00E-05 rs7200786 5.39E-06 486 0.000001 
SOCS1 16 11255774 21 225.7989 1.00E-07 rs12596260 2.21E-06 508 0.0000001 21 173.8217 2.00E-06 rs243324 1.33E-06 486 0.000001 
TNP2 16 11269214 21 267.3649 1.00E-07 rs12928822 4.52E-07 508 0.0000001 21 200.8308 1.00E-06 rs243324 1.33E-06 486 0.000001 
PRM3 16 11274644 21 267.3649 1.00E-07 rs12928822 4.52E-07 508 0.0000001 21 200.8308 1.00E-06 rs243324 1.33E-06 486 0.000001 
PRM2 16 11276993 20 255.2985 1.00E-07 rs12928822 4.52E-07 508 0.0000001 20 192.3831 3.00E-06 rs243324 1.33E-06 486 0.000001 
PRM1 16 11282193 18 243.1464 1.00E-07 rs12928822 4.52E-07 508 0.0000001 18 177.7196 1.00E-06 rs243324 1.33E-06 486 0.000001 
C16orf75 16 11346811 13 116.5316 1.50E-05 rs12928822 4.52E-07 508 0.0000001 13 78.72053 0.000553 rs12928822 8.66E-05 486 0.000001 
LITAF 16 11549356 8 31.6959 0.002179 rs7189692 0.001555 508 0.0000001 NA NA NA NA NA NA NA 
GHDC 17 37594631 NA NA NA NA NA NA NA 2 7.441067 0.03056 rs7214921 0.01134 527 0.000018 
STAT5B 17 37604720 5 16.57455 0.03492 rs8074524 0.02485 545 0.000132 5 37.56669 0.000989 rs8074524 0.000246 527 0.000018 
STAT5A 17 37693090 7 68.10787 0.000219 rs9891119 4.64E-07 545 0.000132 7 88.88289 1.80E-05 rs9891119 2.71E-06 527 0.000018 
STAT3 17 37718868 12 90.7947 0.000132 rs9891119 4.64E-07 545 0.000132 12 101.0319 4.00E-05 rs9891119 2.71E-06 527 0.000018 
PTRF 17 37808000 9 54.90192 0.000277 rs9891119 4.64E-07 545 0.000132 9 50.48688 0.000609 rs9891119 2.71E-06 527 0.000018 
ATP6V0A1 17 37864387 9 50.70907 0.00135 rs8067384 0.0006386 545 0.000132 9 50.48688 0.000533 rs9891119 2.71E-06 527 0.000018 
NAGLU 17 37941476 5 34.27517 0.00173 rs8067384 0.0006386 545 0.000132 NA NA NA NA NA NA NA 
HSD17B1 17 37957509 4 23.07523 0.002021 rs8067384 0.0006386 545 0.000132 NA NA NA NA NA NA NA 
COASY 17 37967617 5 17.14396 0.01955 rs8067384 0.0006386 545 0.000132 NA NA NA NA NA NA NA 
MLX 17 37972603 6 17.54413 0.04177 rs8067384 0.0006386 545 0.000132 NA NA NA NA NA NA NA 
YPEL2 17 54763834 NA NA NA NA NA NA NA 16 41.2151 0.03293 rs2290266 0.002976 533 0.000327 
DHX40 17 54997667 NA NA NA NA NA NA NA 5 34.95887 0.002139 rs7210832 0.000292 533 0.000327 
CLTC 17 55051831 9 40.14034 0.00658 rs7215180 5.61E-05 553 0.000001 9 56.41087 0.000945 rs907066 0.000243 533 0.000327 
PTRH2 17 55129448 7 50.67724 0.000483 rs2777899 4.13E-06 553 0.000001 7 53.20011 0.000327 rs907066 0.000243 533 0.000327 
TMEM49 17 55139644 11 93.71344 3.10E-05 rs2777899 4.13E-06 553 0.000001 11 68.45955 0.000436 rs907066 0.000243 533 0.000327 
TUBD1 17 55291632 5 78.84267 2.00E-06 rs1292053 7.47E-06 553 0.000001 5 24.08787 0.01027 rs1292034 0.001932 533 0.000327 
RPS6KB1 17 55325224 8 112.4098 1.00E-06 rs180515 1.37E-07 553 0.000001 8 36.00879 0.00815 rs1292034 0.001932 533 0.000327 
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RNFT1 17 55384504 6 76.59226 3.00E-06 rs180515 1.37E-07 553 0.000001 6 26.52816 0.00679 rs1292034 0.001932 533 0.000327 
NEDD4L 18 53862777 64 152.0905 0.00801 rs9965182 0.0001464 548 0.000684 NA NA NA NA NA NA NA 
ALPK2 18 54299461 62 115.8401 0.03872 rs11659233 6.55E-05 548 0.000684 59 119.8022 0.02169 rs12456021 7.81E-06 570 0.000207 
MALT1 18 54489597 24 95.42968 0.000684 rs4545915 0.0001299 548 0.000684 24 110.3439 0.000207 rs7238078 2.20E-06 570 0.000207 
MRPL4 19 10223639 15 41.75291 0.01599 rs2569693 0.001163 587 0.0000001 NA NA NA NA NA NA NA 
ICAM1 19 10242516 19 70.74362 0.00131 rs2278442 0.0002943 587 0.0000001 NA NA NA NA NA NA NA 
ICAM4 19 10258649 17 68.57281 0.000749 rs2278442 0.0002943 587 0.0000001 NA NA NA NA NA NA NA 
ICAM5 19 10261654 19 82.45249 0.000275 rs2278442 0.0002943 587 0.0000001 NA NA NA NA NA NA NA 
GLP-1 19 10276478 18 81.82661 0.000233 rs2278442 0.0002943 587 0.0000001 NA NA NA NA NA NA NA 
FDX1L 19 10281890 17 81.24666 0.000213 rs2278442 0.0002943 587 0.0000001 NA NA NA NA NA NA NA 
RAVER1 19 10287888 20 86.30058 0.000256 rs2278442 0.0002943 587 0.0000001 NA NA NA NA NA NA NA 
ICAM3 19 10305451 19 85.59165 0.000201 rs2278442 0.0002943 587 0.0000001 NA NA NA NA NA NA NA 
TYK2 % 19 10322203 13 72.08147 3.70E-05 rs8112449 1.48E-06 587 0.0000001 NA NA NA NA NA NA NA 
CDC37 19 10362808 6 28.88318 0.002356 rs8112449 1.48E-06 587 0.0000001 NA NA NA NA NA NA NA 
PDE4A 19 10392332 8 55.23604 1.00E-07 rs8112449 1.48E-06 587 0.0000001 8 26.02697 0.004797 rs7246953 0.003807 557 0.004797 
KEAP1 19 10457795 8 32.06531 0.00185 rs7246953 4.59E-05 587 0.0000001 8 18.53504 0.03798 rs7246953 0.003807 557 0.004797 
S1PR5 19 10484622 13 37.84331 0.01475 rs7246953 4.59E-05 587 0.0000001 13 39.38159 0.01214 rs7246953 0.003807 557 0.004797 
GMEB2 20 61689398 10 31.73106 0.01743 rs6011002 0.0002361 640 0.000044 NA NA NA NA NA NA NA 
STMN3 20 61741504 11 46.42023 0.00362 rs6011002 0.0002361 640 0.000044 NA NA NA NA NA NA NA 
RTEL1 20 61760090 12 90.32903 4.40E-05 rs2427536 6.78E-05 640 0.000044 12 46.88628 0.00665 rs1151625 0.000537 591 0.00521 
TNFRSF6B 20 61796731 10 87.28124 4.80E-05 rs2427536 6.78E-05 640 0.000044 10 45.52191 0.00583 rs1151625 0.000537 591 0.00521 
ARFRP1 20 61801252 10 87.28124 5.30E-05 rs2427536 6.78E-05 640 0.000044 10 45.52191 0.00521 rs1151625 0.000537 591 0.00521 
ZGPAT 20 61809237 11 87.77265 6.80E-05 rs2427536 6.78E-05 640 0.000044 11 45.82637 0.00692 rs1151625 0.000537 591 0.00521 
LIME1 20 61838421 7 51.32375 0.00074 rs2427536 6.78E-05 640 0.000044 7 31.73595 0.0093 rs1151625 0.000537 591 0.00521 
LIME1 20 61838421 7 51.32375 0.000714 rs2427536 6.78E-05 640 0.000044 7 31.90353 0.00877 rs1151625 0.000537 591 0.00521 
SLC2A4RG 20 61841654 7 49.017 0.000889 rs2427536 6.78E-05 640 0.000044 8 33.6065 0.01039 rs1151625 0.000537 591 0.00521 
ZBTB46 20 61846321 8 60.22284 0.000378 rs2427536 6.78E-05 640 0.000044 NA NA NA NA NA NA NA 
MMP9 20 44070953 NA NA NA NA NA NA NA 5 14.44802 0.04832 rs3933239 0.03001 585 0.00534 
SLC12A5 20 44091244 10 52.28552 0.000208 rs2425752 1.67E-06 630 0.000105 10 33.97052 0.00534 rs2425752 2.76E-05 585 0.00534 
NCOA5 20 44123032 9 56.23764 0.000105 rs2425752 1.67E-06 630 0.000105 9 27.92941 0.01336 rs2425752 2.76E-05 585 0.00534 
CD40 20 44180312 8 52.65425 0.000179 rs2425752 1.67E-06 630 0.000105 8 24.02676 0.02198 rs2425752 2.76E-05 585 0.00534 
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ZNF217 20 51617016 6 27.63551 0.001877 rs1555926 0.00088 636 0.000002 NA NA NA NA NA NA NA 
BCAS1 20 51993485 42 94.39409 0.01318 rs10485442 0.00015 636 0.000002 NA NA NA NA NA NA NA 
CYP24A1 20 52203394 22 148.1899 2.00E-06 rs2248359 5.15E-09 636 0.000002 22 60.7498 0.00861 rs2248359 0.002694 588 0.00861 
PFDN4 20 52257908 13 87.4648 0.000149 rs2248359 5.15E-09 636 0.000002 13 40.99389 0.01813 rs2248359 0.002694 588 0.00861 
PPIL2 22 20350272 20 51.05545 0.02358 rs8139619 0.001244 649 0.000045 NA NA NA NA NA NA NA 
YPEL1 22 20381825 20 99.89337 0.000276 rs2283792 3.99E-06 649 0.000045 19 72.94745 0.00276 rs5999264 0.000551 605 0.000632 
MAPK1 22 20443946 16 125.0074 4.50E-05 rs2283792 3.99E-06 649 0.000045 15 91.61399 0.000632 rs5999264 0.000551 605 0.000632 
PPM1F 22 20603792 14 83.64046 0.000598 rs240066 4.56E-06 649 0.000045 15 61.75075 0.00458 rs240066 0.001107 605 0.000632 
TOP3B 22 20641402 14 77.70595 0.000564 rs240066 4.56E-06 649 0.000045 15 54.12976 0.00695 rs240066 0.001107 605 0.000632 
SBF1 22 49232100 14 41.6213 0.01286 rs131820 0.00024 665 0.000002 NA NA NA NA NA NA NA 
ADM2 22 49266877 12 77.60083 1.20E-05 rs140522 3.85E-06 665 0.000002 12 38.464 0.00522 rs140522 0.004194 612 0.001406 
MIOX 22 49272078 12 86.41554 7.00E-06 rs140522 3.85E-06 665 0.000002 12 46.99273 0.002274 rs140521 0.001953 612 0.001406 
LMF2 22 49288245 11 88.94345 2.00E-06 rs140522 3.85E-06 665 0.000002 10 45.13558 0.001406 rs140521 0.001953 612 0.001406 
NCAPH2 22 49293510 14 101.3098 1.80E-05 rs140522 3.85E-06 665 0.000002 13 52.71693 0.00301 rs140521 0.001953 612 0.001406 
SCO2 22 49308862 11 94.12118 1.20E-05 rs140522 3.85E-06 665 0.000002 10 46.72305 0.00315 rs140521 0.001953 612 0.001406 
TYMP 22 49311047 12 94.34466 1.60E-05 rs140522 3.85E-06 665 0.000002 11 46.72347 0.00363 rs140521 0.001953 612 0.001406 
LOC440836 22 49315720 11 87.57769 2.40E-05 rs140522 3.85E-06 665 0.000002 10 45.38894 0.00396 rs140521 0.001953 612 0.001406 
KLHDC7B 22 49333327 13 93.14997 8.00E-05 rs140522 3.85E-06 665 0.000002 12 47.40411 0.00739 rs140521 0.001953 612 0.001406 
LOC644186 22 49336406 14 97.52122 8.70E-05 rs140522 3.85E-06 665 0.000002 13 49.7026 0.00807 rs140521 0.001953 612 0.001406 
CHKB 22 49354155 13 71.70785 0.000501 rs140522 3.85E-06 665 0.000002 12 36.75617 0.01882 rs140521 0.001953 612 0.001406 
CPT1B 22 49354155 13 71.70785 0.00049 rs140522 3.85E-06 665 0.000002 12 36.75617 0.0199 rs140521 0.001953 612 0.001406 
MAPK8IP2 22 49385996 10 25.45299 0.03745 rs140518 0.00379 665 0.000002 NA NA NA NA NA NA NA 
                 
* S1PR1 is significant in both studies but falls in a contiguous block in meta2.5           
# MYB is borderline significant in meta2.5 (p=0.536)             
% TYK2 is not significant in meta2.5               
rows in red represent genes with p-values in both studies and identified in the intersection network (candidates)        
Rows in bold represent bona-fide MS susceptibility genes             
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Supplementary Table 3. Candidate susceptibility variant-containing genes 
    WTCCC2 Meta2.5 
Gene Chr Start nSNPs Test Pvalue Best.SNP SNP.pvalue block 
block 
best 
pvalue nSNPs Test Pvalue Best.SNP SNP.pvalue block 
block best 
pvalue 
SYDE2 1 85395943 13 35.22858 0.02408 rs17382610 0.002596 28 0.000021 NA NA NA NA NA NA NA 
C1orf52 1 85490243 20 135.824 2.50E-05 rs2030075 9.61E-06 28 0.000021 20 95.39334 0.000676 rs2030075 1.98E-05 27 0.000541 
BCL10 1 85504047 21 137.7897 2.10E-05 rs2030075 9.61E-06 28 0.000021 21 99.62914 0.000541 rs2030075 1.98E-05 27 0.000541 
DDAH1 1 85556755 33 139.9095 0.00133 rs2030075 9.61E-06 28 0.000021 33 110.6173 0.00451 rs2030075 1.98E-05 27 0.000541 
ZNF697 1 1.2E+08 16 41.03661 0.01711 rs639216 0.00046 37 0.000823 15 62.25939 0.00083 rs639216 1.06E-05 38 0.000117 
PHGDH 1 1.2E+08 19 82.24214 0.000823 rs639216 0.00046 37 0.000823 19 102.1858 0.000117 rs639216 1.06E-05 38 0.000117 
HMGCS2 1 1.2E+08 18 54.77674 0.0092 rs592762 0.00528 37 0.000823 18 50.11705 0.01403 rs592762 1.75E-05 38 0.000117 
SLAMF1 1 1.59E+08 13 38.75361 0.008 rs3795324 0.0004 44 0.000009 15 29.98571 0.0497 rs3795324 0.02557 49 0.00344 
CD48 1 1.59E+08 12 62.79755 9.00E-06 rs983494 0.00015 44 0.000009 13 33.50673 0.00902 rs983494 0.001565 49 0.00344 
SLAMF7 1 1.59E+08 8 38.8205 0.000499 rs983494 0.00015 44 0.000009 8 30.0873 0.00344 rs983494 0.001565 49 0.00344 
PAPOLG 2 60836886 16 54.764 0.01058 rs4672410 0.0009812 80 0.00032 16 50.14943 0.01714 rs1432295 0.003367 82 0.000471 
REL 2 60962255 16 112.4797 0.00032 rs12713430 0.0002975 80 0.00032 16 107.5495 0.000471 rs13031237 4.35E-05 82 0.000471 
PUS10 2 61022607 16 101.1383 0.000445 rs1177279 0.0002473 80 0.00032 16 99.31703 0.000511 rs13031237 4.35E-05 82 0.000471 
PEX13 2 61098373 10 64.32374 0.001132 rs1177279 0.0002473 80 0.00032 10 30.85147 0.03566 rs12988616 0.000633 82 0.000471 
KIAA1841 2 61146509 14 78.35492 0.001928 rs1177279 0.0002473 80 0.00032 14 45.37361 0.02417 rs12988616 0.000633 82 0.000471 
AHSA2 2 61258324 8 22.29219 0.03629 rs2290324 0.004378 80 0.00032 NA NA NA NA NA NA NA 
USP34 2 61268093 20 54.96053 0.03312 rs2290324 0.004378 80 0.00032 NA NA NA NA NA NA NA 
XPO1 2 61558572 9 27.1636 0.03235 rs778139 0.01006 80 0.00032 NA NA NA NA NA NA NA 
NPAL1 4 47713547 12 36.36775 0.02011 rs4340770 0.002227 173 0.000171 NA NA NA NA NA NA NA 
TXK 4 47763166 19 116.4092 0.000171 rs17471024 6.21E-05 173 0.000171 20 109.7325 0.000392 rs17470892 1.44E-05 153 0.000392 
TEC 4 47832556 33 137.1188 0.000717 rs17471024 6.21E-05 173 0.000171 33 142.8695 0.000476 rs17470892 1.44E-05 153 0.000392 
IL3 5 1.31E+08 11 38.55111 0.01816 rs3864277 0.00077 206 0.01117 11 39.55668 0.01759 rs152198 0.002281 195 0.000809 
CSF2 5 1.31E+08 10 43.20431 0.01117 rs3864277 0.00077 206 0.01117 10 47.58008 0.00755 rs152198 0.002281 195 0.000809 
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P4HA2 5 1.32E+08 13 40.41141 0.02531 rs715285 0.00397 206 0.01117 13 74.17733 0.00087 rs2077380 3.34E-05 195 0.000809 
PDLIM4 5 1.32E+08 NA NA NA NA NA NA NA 18 95.06358 0.000809 rs2077380 3.34E-05 195 0.000809 
SLC22A4 5 1.32E+08 NA NA NA NA NA NA NA 22 75.75723 0.0115 rs3792884 6.20E-05 195 0.000809 
LOC441108 5 1.32E+08 NA NA NA NA NA NA NA 23 78.76226 0.00855 rs2070729 0.004761 196 0.00855 
IRF1 5 1.32E+08 16 66.37171 0.00359 rs4143832 0.00172 207 0.000518 16 54.99436 0.01076 rs2070729 0.004761 196 0.00855 
IL5 5 1.32E+08 6 37.62761 0.000518 rs4143832 0.00172 207 0.000518 NA NA NA NA NA NA NA 
RAD50 5 1.32E+08 9 33.87905 0.0191 rs4143832 0.00172 207 0.000518 NA NA NA NA NA NA NA 
EIF3B 7 2360999 11 75.60162 5.20E-05 rs6952809 3.37E-05 266 0.000052 11 28.02535 0.03787 rs1548597 0.002413 257 0.03787 
CHST12 7 2409784 13 66.20979 0.000148 rs6952809 3.37E-05 266 0.000052 13 29.65083 0.04015 rs1548597 0.002413 257 0.03787 
RCL1 9 4782833 NA NA NA NA NA NA NA 34 69.27655 0.04209 rs7038267 0.0203 306 0.01543 
JAK2 9 4975244 12 40.51604 0.00996 rs12347727 0.00724 322 0.00996 12 36.5556 0.01543 rs17718680 0.000531 306 0.01543 
INSL6 9 5153862 6 37.92267 0.01117 rs10491651 0.0089 322 0.00996 NA NA NA NA NA NA NA 
INSL4 9 5221418 5 31.9956 0.01026 rs10491651 0.0089 322 0.00996 NA NA NA NA NA NA NA 
PAX5 9 36828530 31 65.82323 0.02318 rs7020413 0.00813 331 0.02318 29 54.7537 0.04573 rs3824344 0.004943 315 0.04573 
SCGB1C1 11 183079 16 60.50627 0.01027 rs4980335 0.00104 374 0.000924 NA NA NA NA NA NA NA 
ODF3 11 186760 19 67.05872 0.00986 rs4980335 0.00104 374 0.000924 19 51.41517 0.03122 rs498217 0.008865 364 0.0092 
BET1L 11 192923 22 77.35674 0.00635 rs4980335 0.00104 374 0.000924 22 58.84193 0.02568 rs498217 0.008865 364 0.0092 
RIC8A 11 198529 23 80.34385 0.00608 rs4980335 0.00104 374 0.000924 23 59.7456 0.02786 rs498217 0.008865 364 0.0092 
SIRT3 11 205029 25 83.58659 0.00665 rs4980335 0.00104 374 0.000924 25 65.37202 0.02608 rs498217 0.008865 364 0.0092 
PSMD13 11 226807 26 89.1471 0.00537 rs4980335 0.00104 374 0.000924 26 69.14908 0.02084 rs498217 0.008865 364 0.0092 
NLRP6 11 268569 18 72.15861 0.001152 rs10398 0.00011 374 0.000924 18 53.55222 0.0092 rs498217 0.008865 364 0.0092 
ATHL1 11 279137 16 57.02261 0.00169 rs10398 0.00011 374 0.000924 16 41.89066 0.01512 rs498217 0.008865 364 0.0092 
IFITM5 11 288202 12 43.73017 0.00249 rs10398 0.00011 374 0.000924 12 29.51358 0.02492 rs498217 0.008865 364 0.0092 
IFITM2 11 298106 10 32.64602 0.002805 rs10398 0.00011 374 0.000924 NA NA NA NA NA NA NA 
IFITM1 11 303990 10 32.64602 0.00308 rs10398 0.00011 374 0.000924 NA NA NA NA NA NA NA 
IFITM3 11 309672 8 29.01861 0.000924 rs10398 0.00011 374 0.000924 NA NA NA NA NA NA NA 
F2 11 46697318 NA NA NA NA NA NA NA 6 19.21001 0.02747 rs4752932 0.009175 376 0.000912 
CKAP5 11 46721659 NA NA NA NA NA NA NA 7 32.09703 0.01242 rs2306033 0.007294 376 0.000912 
LRP4 11 46834993 NA NA NA NA NA NA NA 6 46.58391 0.000912 rs11039035 0.000869 376 0.000912 
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C11orf49 11 46914826 NA NA NA NA NA NA NA 17 97.64172 0.00258 rs11039035 0.000869 376 0.000912 
ARFGAP2 11 47142427 NA NA NA NA NA NA NA 11 32.17387 0.0311 rs4752965 0.001204 376 0.000912 
DDB2 11 47193068 10 46.32739 0.00125 rs7120118 0.00119 392 0.000693 12 41.07689 0.01674 rs4752965 0.001204 376 0.000912 
ACP2 11 47217428 10 54.34377 0.000699 rs7120118 0.00119 392 0.000693 10 45.11937 0.001639 rs7120118 0.002127 376 0.000912 
ACP2 11 47217428 10 54.34377 0.000727 rs7120118 0.00119 392 0.000693 10 40.17069 0.00449 rs7120118 0.002127 376 0.000912 
NR1H3 11 47227024 10 54.34377 0.000693 rs7120118 0.00119 392 0.000693 10 40.17069 0.00472 rs7120118 0.002127 376 0.000912 
MADD 11 47247534 11 63.66385 0.000801 rs7120118 0.00119 392 0.000693 12 48.97574 0.00493 rs10838692 0.001829 376 0.000912 
MYBPC3 11 47309532 8 32.96426 0.00924 rs10838692 0.00122 392 0.000693 9 30.67595 0.01528 rs10838692 0.001829 376 0.000912 
NA NA NA NA NA NA NA NA NA NA 11 30.85144 0.04229 rs10838692 0.001829 376 0.000912 
CCDC85B 11 65414450 7 18.73915 0.04959 rs500161 0.002054 399 0.000038 NA NA NA NA NA NA NA 
FOSL1 11 65416267 8 35.90855 0.00701 rs606978 3.42E-05 399 0.000038 8 27.04747 0.02244 rs500161 0.003384 382 0.001148 
C11orf68 11 65440858 7 50.11993 0.000614 rs606978 3.42E-05 399 0.000038 8 33.0662 0.01356 rs500161 0.003384 382 0.001148 
DRAP1 11 65443303 7 50.11993 0.000649 rs606978 3.42E-05 399 0.000038 8 33.0662 0.01268 rs500161 0.003384 382 0.001148 
TSGA10IP 11 65469690 12 90.65737 0.000269 rs606978 3.42E-05 399 0.000038 13 83.55566 0.001171 rs754532 0.000103 382 0.001148 
SART1 11 65485735 11 93.4897 0.000112 rs606978 3.42E-05 399 0.000038 12 76.73825 0.001148 rs754532 0.000103 382 0.001148 
EIF1AD 11 65520592 11 78.72116 9.50E-05 rs613924 5.81E-05 399 0.000038 12 60.73457 0.001775 rs754532 0.000103 382 0.001148 
BANF1 11 65526125 12 91.65904 3.80E-05 rs613924 5.81E-05 399 0.000038 13 60.87515 0.00254 rs754532 0.000103 382 0.001148 
CST6 11 65536037 11 76.01615 7.50E-05 rs613924 5.81E-05 399 0.000038 12 57.10035 0.001942 rs754532 0.000103 382 0.001148 
CATSPER1 11 65540798 11 76.01615 7.20E-05 rs613924 5.81E-05 399 0.000038 11 53.21847 0.00157 rs754532 0.000103 382 0.001148 
GAL3ST3 11 65564811 10 66.21519 0.000157 rs613924 5.81E-05 399 0.000038 10 24.98483 0.04717 rs747526 0.0003 382 0.001148 
SF3B2 11 65576391 9 51.36033 0.00114 rs503156 0.000322 399 0.000038 NA NA NA NA NA NA NA 
PACS1 11 65594399 17 50.18067 0.02364 rs503156 0.000322 399 0.000038 NA NA NA NA NA NA NA 
ETS1 11 1.28E+08 34 81.39607 0.01218 rs4245079 0.00044 418 0.01218 34 75.25326 0.02008 rs7122859 0.001589 395 0.02008 
BCL7A 12 1.21E+08 5 13.34707 0.04572 rs11043307 0.04298 451 0.000919 5 35.92612 0.000254 rs11835818 0.000236 428 0.000046 
MLXIP 12 1.21E+08 14 73.20462 0.00355 rs2292443 0.0003 451 0.000919 14 106.1202 0.000163 rs1047796 0.00013 428 0.000046 
LRRC43 12 1.21E+08 13 64.22273 0.00276 rs2292443 0.0003 451 0.000919 13 79.93842 0.000357 rs1047796 0.00013 428 0.000046 
IL31 12 1.21E+08 12 63.44227 0.00239 rs2292443 0.0003 451 0.000919 12 72.28707 0.000677 rs1047796 0.00013 428 0.000046 
B3GNT4 12 1.21E+08 8 45.69593 0.001238 rs2292443 0.0003 451 0.000919 9 40.10194 0.00448 rs11611988 0.003876 428 0.000046 
DIABLO 12 1.21E+08 8 44.71881 0.000919 rs2292443 0.0003 451 0.000919 9 46.97952 0.001075 rs907482 0.00203 428 0.000046 
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VPS33A 12 1.21E+08 7 27.38524 0.00909 rs2292443 0.0003 451 0.000919 8 43.04591 0.001237 rs4758670 0.000971 428 0.000046 
CLIP1 12 1.21E+08 11 45.92899 0.00495 rs7301515 0.00297 451 0.000919 10 72.45726 4.60E-05 rs10846921 0.000313 428 0.000046 
ZCCHC8 12 1.22E+08 9 33.44878 0.02227 rs7301515 0.00297 451 0.000919 8 64.37445 0.000403 rs10846921 0.000313 428 0.000046 
RSRC2 12 1.22E+08 9 28.58497 0.03052 rs7301515 0.00297 451 0.000919 9 65.89722 0.00045 rs10846921 0.000313 428 0.000046 
RSRC2 12 1.22E+08 NA NA NA NA NA NA NA 9 65.89722 0.000439 rs10846921 0.000313 428 0.000046 
KNTC1 12 1.22E+08 NA NA NA NA NA NA NA 14 77.3776 0.001221 rs7968222 0.000848 428 0.000046 
RCOR1 14 1.02E+08 NA NA NA NA NA NA NA 19 74.73825 0.00376 rs8010152 0.000166 465 0.00113 
TRAF3 14 1.02E+08 21 103.0882 0.001292 rs12148050 3.48E-05 487 0.001292 21 104.1795 0.00113 rs941726 7.51E-05 465 0.00113 
AMN 14 1.02E+08 8 33.66006 0.01123 rs2273393 0.01305 487 0.001292 NA NA NA NA NA NA NA 
CDC42BPB 14 1.02E+08 16 41.81444 0.02619 rs2273393 0.01305 487 0.001292 NA NA NA NA NA NA NA 
MARK3 14 1.03E+08 21 86.42348 0.00663 rs3783394 0.00076 488 0.00663 21 154.7726 9.60E-05 rs1467561 1.69E-05 466 0.000096 
CKB 14 1.03E+08 13 43.58392 0.02412 rs1467561 0.00218 488 0.00663 13 91.9596 0.000352 rs1467561 1.69E-05 466 0.000096 
C14orf172 14 1.03E+08 11 32.02248 0.04165 rs1467561 0.00218 488 0.00663 11 67.16573 0.00136 rs1467561 1.69E-05 466 0.000096 
BAG5 14 1.03E+08 NA NA NA NA NA NA NA 10 39.16304 0.01533 rs1467561 1.69E-05 466 0.000096 
C14orf153 14 1.03E+08 NA NA NA NA NA NA NA 12 49.38119 0.01032 rs1467561 1.69E-05 466 0.000096 
KLC1 14 1.03E+08 NA NA NA NA NA NA NA 14 44.81477 0.02751 rs11160755 0.02118 466 0.000096 
XRCC3 14 1.03E+08 NA NA NA NA NA NA NA 10 26.30876 0.04738 rs8007903 0.02955 466 0.000096 
ZFYVE21 14 1.03E+08 NA NA NA NA NA NA NA 10 26.30876 0.04612 rs8007903 0.02955 466 0.000096 
ITGAM 16 31178788 13 56.1471 0.003134 rs7193268 0.00089 514 0.002478 13 35.52077 0.03216 rs1143678 0.00924 492 0.01925 
ITGAX 16 31274009 12 50.7809 0.002478 rs7193268 0.00089 514 0.002478 12 35.4042 0.01925 rs1143678 0.00924 492 0.01925 
ITGAD 16 31312133 12 32.05143 0.02253 rs11574637 0.00325 514 0.002478 NA NA NA NA NA NA NA 
C17orf57 17 42756348 12 40.98834 0.01166 rs4968318 0.003165 548 0.000157 12 53.79474 0.00259 rs9893901 3.03E-05 530 0.0000001 
NPEPPS 17 42963442 4 36.90127 0.000519 rs11079784 0.0001316 548 0.000157 4 73.46174 1E-07 rs11079784 4.36E-07 530 0.0000001 
KPNB1 17 43082273 7 62.55541 0.000157 rs11079784 0.0001316 548 0.000157 7 105.8437 1E-07 rs11079784 4.36E-07 530 0.0000001 
TBKBP1 17 43127628 8 50.71565 0.000898 rs16942199 0.0001784 548 0.000157 8 90.2871 5.00E-06 rs8078686 6.48E-07 530 0.0000001 
TBX21 17 43165608 8 33.93278 0.00371 rs16942199 0.0001784 548 0.000157 8 50.93979 2.00E-04 rs4794053 4.95E-06 530 0.0000001 
UNK 17 71292275 NA NA NA NA NA NA NA 10 34.25729 0.00895 rs3744017 0.00012 540 0.000681 
UNC13D 17 71334901 NA NA NA NA NA NA NA 7 43.89598 0.000681 rs3744017 0.00012 540 0.000681 
WBP2 17 71353374 7 22.24762 0.02328 rs17581728 0.00571 560 0.00105 7 39.17802 0.001208 rs3744017 0.00012 540 0.000681 
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TRIM47 17 71381839 10 28.52824 0.03587 rs17581728 0.00571 560 0.00105 10 55.4887 0.00205 rs3744017 0.00012 540 0.000681 
TRIM65 17 71396635 10 36.8546 0.02248 rs1135889 0.00182 560 0.00105 10 56.14763 0.00417 rs3744017 0.00012 540 0.000681 
MRPL38 17 71406318 10 36.8546 0.02192 rs1135889 0.00182 560 0.00105 10 56.14763 0.0038 rs3744017 0.00012 540 0.000681 
FBF1 17 71418212 13 38.367 0.02324 rs1135889 0.00182 560 0.00105 13 51.43853 0.00657 rs3744017 0.00012 540 0.000681 
ACOX1 17 71449186 15 48.7562 0.00969 rs2069528 0.00162 560 0.00105 NA NA NA NA NA NA NA 
CDK3 17 71508581 9 22.59152 0.02884 rs2069528 0.00162 560 0.00105 NA NA NA NA NA NA NA 
EVPL 17 71514521 11 31.04031 0.01304 rs2069528 0.00162 560 0.00105 NA NA NA NA NA NA NA 
SRP68 17 71546785 10 51.91117 0.00105 rs2305347 0.00044 560 0.00105 NA NA NA NA NA NA NA 
GALR2 17 71582486 7 39.19201 0.00272 rs2305347 0.00044 560 0.00105 NA NA NA NA NA NA NA 
ZACN 17 71586903 7 39.19201 0.00265 rs2305347 0.00044 560 0.00105 NA NA NA NA NA NA NA 
EXOC7 17 71588681 9 43.08315 0.00267 rs2305347 0.00044 560 0.00105 NA NA NA NA NA NA NA 
KLF2 19 16296650 8 36.62655 6.00E-04 rs6512102 0.0003152 590 0.000311 8 31.92793 0.00173 rs6512102 1.26E-06 559 0.0000001 
EPS15L1 19 16333407 16 88.48963 0.000311 rs11878602 0.0002781 590 0.000311 16 180.1105 1E-07 rs11878602 2.37E-07 559 0.0000001 
CALR3 19 16450874 7 36.32593 0.002296 rs11878602 0.0002781 590 0.000311 7 100.8443 1E-07 rs11878602 2.37E-07 559 0.0000001 
C19orf44 19 16468204 7 30.63249 0.00592 rs1544768 0.001654 590 0.000311 7 78.28756 6.00E-06 rs10412060 2.06E-06 559 0.0000001 
CHERP 19 16489699 9 50.4809 0.00176 rs754292 0.001406 590 0.000311 9 94.55979 1.60E-05 rs10412060 2.06E-06 559 0.0000001 
SLC35E1 19 16521647 10 48.91913 0.00242 rs754292 0.001406 590 0.000311 10 79.88877 5.50E-05 rs11667601 7.23E-05 559 0.0000001 
MED26 19 16546717 12 53.63174 0.000963 rs754292 0.001406 590 0.000311 12 65.92748 0.000201 rs11667601 7.23E-05 559 0.0000001 
C19orf42 19 16617958 NA NA NA NA NA NA NA 8 26.50736 0.00741 rs3786601 7.96E-05 559 0.0000001 
TMEM38A 19 16632937 NA NA NA NA NA NA NA 8 19.84108 0.03002 rs3786601 7.96E-05 559 0.0000001 
IL12RB1 19 18031370 14 78.26269 0.000143 rs740691 8.83E-07 592 0.0000001 NA NA NA NA NA NA NA 
MAST3 19 18069602 15 155.0089 1.00E-07 rs874628 4.32E-08 592 0.0000001 15 46.74158 0.01644 rs874628 0.00228 560 0.00872 
PIK3R2 19 18125015 16 181.4169 1.00E-07 rs874628 4.32E-08 592 0.0000001 16 52.53453 0.01093 rs4808762 0.000788 560 0.00872 
IFI30 19 18145578 15 151.5595 1.00E-06 rs874628 4.32E-08 592 0.0000001 15 50.68946 0.00872 rs4808762 0.000788 560 0.00872 
FKSG24 19 18165039 15 136.032 1.00E-06 rs874628 4.32E-08 592 0.0000001 15 49.3563 0.01059 rs4808762 0.000788 560 0.00872 
RAB3A 19 18168610 14 112.6513 1.10E-05 rs874628 4.32E-08 592 0.0000001 14 44.74111 0.01381 rs4808762 0.000788 560 0.00872 
PDE4C 19 18179770 21 194.0875 3.00E-06 rs874628 4.32E-08 592 0.0000001 22 54.50826 0.03916 rs4808762 0.000788 560 0.00872 
KIAA1683 19 18228907 19 131.659 2.20E-05 rs12608504 6.53E-07 592 0.0000001 NA NA NA NA NA NA NA 
JUND 19 18251562 15 90.5547 0.000287 rs12608504 6.53E-07 592 0.0000001 NA NA NA NA NA NA NA 
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LSM4 19 18278716 21 93.28058 0.000142 rs12608504 6.53E-07 592 0.0000001 NA NA NA NA NA NA NA 
MN1 22 26474264 7 19.47515 0.01412 rs9625312 0.00155 651 0.00592 NA NA NA NA NA NA NA 
PITPNB 22 26577656 8 30.59403 0.00592 rs12169097 0.00449 651 0.00592 8 24.8884 0.01738 rs12170161 0.006413 606 0.01738 
PVALB 22 35526690 11 42.14601 0.00525 rs4821544 0.0001105 656 0.000001 10 36.73486 0.00438 rs741997 0.000261 607 0.00438 
NCF4 22 35586975 18 174.2993 1.00E-06 rs2413436 8.72E-06 656 0.000001 18 56.4745 0.01512 rs741997 0.000261 607 0.00438 
CSF2RB* 22 35639620 18 139.1452 2.80E-05 rs2413436 8.72E-06 656 0.000001 18 27.62367 0.163 rs2413436 0.01541 NA 0.163 
* CSF2RB is not significant in meta2.5 (p=0.163)             
rows in red represent genes with p-values in both studies and identified in the intersection network (candidates)        
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